Margaret Gatti-Mays: A great option for our patients with TNBC

Margaret Gatti-Mays, Associate Professor in the Division of Medical Oncology at the OSUCCC – James Cancer Hospital and Solove Research Institute, shared Dana-Farber’s Breast Oncology Center’s post on X/Twitter, adding:

“Excited to be opening OptimICE-pCR at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute SSCBC soon! A great option for our patients with TNBC and will help answer an important question regarding need of adjuvant pembrolizumab in patients with pCR after neoadjuvant chemo-IO.”

Quoting Dana-Farber’s Breast Oncology Center’s post:

“Poster PO4-19-05 | OptimICE-pCR De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemo + checkpoint inhibitor therapy.”

Source: Margaret Gatti-Mays/X and Dana-Farber’s Breast Oncology Center/X